Today’s Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 percent to close at 24,283.11, while the S&P 500 Index gained 0.22 percent to close at 2,723.06. The Nasdaq Composite Index jumped 0.39 percent to close at 7,561.63.

“The market is trading more on sentiment than fundamentals lately, which means moves are likely to be fickle and short lived,” said Liz Young, senior investment strategist at BNY Mellon Investment Management, according to MarketWatch.

“We feel that while momentum around trade is escalating, we’re still in a place where it’s in every nation’s best interest to avoid that outcome, and that things could calm down as negotiations progress,” she said. “In the meantime, the economy is still strong, data is moving in the right direction, and we don’t see this as the issue that will turn things around.”

RDI Initiates Coverage on:

Amicus Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=FOLD

Sage Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=SAGE

Amicus Therapeutics’ stock moved 0.85% higher Tuesday, to close the day at $15.49. The stock recorded a trading volume of 1,382,249 shares, which was below its three months average volume of 2,320,609 shares. In the last year, Amicus Therapeutics’ shares have traded in a range of 9.53 – 17.62. The share price has gained 62.54% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $15.80 is above its 200-day moving average of $14.99. Shares of Amicus Therapeutics have fallen roughly 1.90 percent in the past month and are up 7.64 percent year-to-date.

Access RDI’s Amicus Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FOLD

On Tuesday, shares of Sage Therapeutics recorded a trading volume of 782,162 shares, which was above the three months average volume of 586,157 shares. The stock ended the day 4.88% higher at $154.01. The share price has fallen 21.41% from its 52 week high with a 52 week trading range of 59.57 – 195.97. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $160.46 is below its 200-day moving average of $163.51. Shares of Sage Therapeutics have fallen roughly 0.85 percent in the past month and are down 6.5 percent year-to-date.

Access RDI’s Sage Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SAGE

Our Actionable Research on Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Sage Therapeutics, Inc. (NASDAQ:SAGE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 503873